Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLUTION: Golimumab in Ulcerative Colitis
NCT02318667Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2015
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of golimumab in ulcerative colitis (UC), sponsored by Merck & Co.. Started Feb 2015; status: completed.
02
Drugs
golimumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02318667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318667.